Botulinum Toxin as a Functional Rehabilitation Tool: Integration between Aesthetics, Quality of Life, and Public Health

Botulinum toxin, traditionally associated with facial aesthetics, has consolidated itself in recent decades as a relevant tool in the functional rehabilitation of patients with facial paralysis, poststroke spasticity, dystonias, and chronic headache, with a direct impact on quality of life, functional autonomy, and public health outcomes. Clinical studies and systematic reviews demonstrate significant improvement in facial asymmetry, pain, spasticity, and functional limitation, resulting in greater independence for activities of daily living, improved occupational performance, and social reintegration. This article aims to analyze, in light of recent literature, the role of botulinum toxin as a functional rehabilitation tool, integrating clinical evidence, quality-of-life outcomes, and public health implications. This is an integrative literature review, with a structured search in the PubMed, SciELO, Cochrane Library, and complementary sources, including clinical trials, observational studies, systematic reviews, meta-analyses, and guidelines that evaluate the therapeutic use of botulinum toxin in facial paralysis, post-stroke spasticity, and chronic headache. Studies that presented quantitative outcomes of function, spasticity, pain, and quality of life were included, allowing for the comparison and critical synthesis of the results. The findings demonstrate that botulinum toxin type A consistently reduces upper limb spasticity in post-stroke patients in samples of up to 782 patients, with significant improvement on muscle tone scales, although the direct translation of these gains into function presents results that are still heterogeneous across studies. In facial paralysis, research with samples of up to 88 patients demonstrates sustained improvement in quality-of-life scores up to four months after injections, with reduction of asymmetries, synkinesis, and anxiety-depressive symptoms. In chronic headache, randomized trials with 1,384 adults indicate a mean reduction of 8.4 headache days per month, accompanied by relevant gains in functionality, vitality, and participation in social and professional activities. It is concluded that botulinum toxin should be understood as a functional rehabilitation technology, and not merely as an optional aesthetic resource, with the potential to integrate public health protocols directed at patients with neurological sequelae, chronic pain, and deforming conditions. In particular, its applicability stands out in systems that serve war veterans, stroke survivors, craniofacial trauma patients, and other disabling conditions, in which adequate management of spasticity, pain, and facial asymmetry can reduce indirect costs, improve work capacity, and promote lasting social inclusion.